Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05088356 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | active not recruiting | Phase 1 | 66 | Stanford UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | active not recruiting | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05688475 | A Rollover Study of CC-122 | active not recruiting | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 4 | May 11, 2026 | clinicaltrials |
| NCT04817007 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | active not recruiting | Phase 1 / Phase 2 | 216 | Bristol-Myers SquibbINDUSTRY | 11 | May 8, 2026 | clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06014762 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | active not recruiting | Phase 1 | 120 | Poseida Therapeutics, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | active not recruiting | Phase 1 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT05400109 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | active not recruiting | Phase 1 | 21 | David WaldOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | active not recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | active not recruiting | Phase 1 | 74 | Ascentage Pharma Group Inc.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT02993146 | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05347225 | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | active not recruiting | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02732275 | DS-3201b in Participants With Lymphomas | active not recruiting | Phase 1 | 100 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma(MM) | active not recruiting | Phase 1 | 275 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04939272 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | active not recruiting | Phase 1 | 17 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT00466531 | Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04667663 | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.(CPD-DARA) | active not recruiting | Phase 1 | 16 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT01054196 | Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study | active not recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | active not recruiting | Phase 1 / Phase 2 | 153 | Autolus LimitedINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT03085173 | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03240211 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | active not recruiting | Phase 1 | 37 | University of VirginiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03922035 | CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant | active not recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03431090 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | active not recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05411497 | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms(LIMBER) | active not recruiting | Phase 1 | 140 | Incyte CorporationINDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT02051257 | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 51 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04980404 | Inqovi Maintenance Therapy in Myeloid Neoplasms | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06645886 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 13 | Kumquat Biosciences Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2026source: clinicaltrials